Publish date:

Five Top Stock Gainers for Tuesday: Under Armour, ZoomInfo, Translate Bio

Under Armour, ZoomInfo, Translate Bio, Outlook Therapeutics and Arcturus Therapeutics are five top gainers for Tuesday.

Stocks finished higher Tuesday as solid earnings reports outweighed jitters about the spread of COVID-19's delta variant and China's clampdown on its gaming and technology sectors.

Here are some of the market's biggest gainers for Tuesday:

1. Under Armour | Increase 7.6%

Under Armour  (UAA) - Get Under Armour, Inc. Class A Report shares spiked after the sports-apparel company posted stronger-than-expected second-quarter earnings and boosted its 2021 sales forecast. Revenue rose 91% to $1.4 billion, topping the consensus analyst estimate of $1.2 billion.

2. ZoomInfo Technologies | Increase 3.1%

ZoomInfo Technologies  (ZI) - Get ZoomInfo Technologies Report shares climbed after the cloud-based data platform for sales-and-marketing applications beat Wall Street's second-quarter-earnings expectations. Earnings doubled to 14 cents a share, beating the Zacks consensus estimate of 12 cents. Revenue totaled $174 million, up 57% from a year earlier.

TheStreet Recommends

3. Translate Bio | Increase 29%

Shares of Translate Bio  (TBIO) - Get Translate Bio, Inc. Report surged after French drugmaker Sanofi  (SNY) - Get Sanofi Sponsored ADR Report agreed to buy its messenger-RNA development partner for $3.2 billion cash. Sanofi said it would pay $38 for each of Translate Bio’s shares. The transaction has been approved by the boards of both companies.

4. Outlook Therapeutics | Increase 6.6%

Outlook Therapeutics  (OTLK) - Get Outlook Therapeutics, Inc. Report shares climbed after the biopharmaceutical company reported positive results for its treatment of neovascular age-related macular degeneration, or wet AMD, ONS-5010/Lytenava. The trial enrolled a total of 228 subjects with wet AMD across 39 clinical trial sites in the U.S.

5. Arcturus Therapeutics | Increase 68%

Shares of Arcturus Therapeutics  (ARCT) - Get Arcturus Therapeutics Holdings, Inc. Report surged after the biotech said the Singapore Health Sciences Authority approved the advancement of two messenger RNA COVID-19 vaccine candidates into Phase 1/2 clinical testing.